IL35341A - Antibiotic synergistic compositions containing primycin and another antibiotic and their preparation - Google Patents

Antibiotic synergistic compositions containing primycin and another antibiotic and their preparation

Info

Publication number: IL35341A
Authority: IL; Israel
Prior art keywords: antibiotic; primycin; derivatives; compositions; antibiotics
Prior art date: 1969-09-30

Application number

IL35341A

Other languages

English (en)

Other versions

IL35341A0 (en

Original Assignee

Chinoin Gyogyszer Es Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1969-09-30

Filing date

1970-09-24

Publication date

1974-11-29

1970-09-24 Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet

1970-11-30 Publication of IL35341A0 publication Critical patent/IL35341A0/xx

1974-11-29 Publication of IL35341A publication Critical patent/IL35341A/en

Links

NYWSLZMTZNODJM-MCGDBQAWSA-N 2-[5-[(4e,20e)-35-butyl-19-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-10,12,14,16,18,22,26,30,34-nonahydroxy-3,5,21,33-tetramethyl-36-oxo-1-oxacyclohexatriaconta-4,20-dien-2-yl]-4-hydroxyhexyl]guanidine Chemical compound OC1CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(C(C)C(O)CCCN=C(N)N)OC(=O)C(CCCC)C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NYWSLZMTZNODJM-MCGDBQAWSA-N 0.000 title claims description 55
229950010664 primycin Drugs 0.000 title claims description 55
NYWSLZMTZNODJM-SDUQVVOESA-N primycin Natural products CCCC[C@H]1[C@H](O)[C@H](C)CC[C@@H](O)CCC[C@@H](O)CCC[C@@H](O)C(=C[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@H](O)CCCCC(=C[C@@H](C)[C@@H](OC1=O)[C@H](C)[C@H](O)CCCNC(=N)N)C)C NYWSLZMTZNODJM-SDUQVVOESA-N 0.000 title claims description 55
239000000203 mixture Substances 0.000 title claims description 41
230000003115 biocidal effect Effects 0.000 title claims description 28
230000002195 synergetic effect Effects 0.000 title claims description 18
238000002360 preparation method Methods 0.000 title claims description 7
239000003242 anti bacterial agent Substances 0.000 claims description 17
229940088710 antibiotic agent Drugs 0.000 claims description 16
229930193140 Neomycin Natural products 0.000 claims description 14
229960004927 neomycin Drugs 0.000 claims description 14
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 10
238000000034 method Methods 0.000 claims description 10
229960005322 streptomycin Drugs 0.000 claims description 7
OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 claims description 6
108010015940 Viomycin Proteins 0.000 claims description 6
GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 claims description 6
229950001272 viomycin Drugs 0.000 claims description 6
239000000969 carrier Substances 0.000 claims description 5
239000004098 Tetracycline Substances 0.000 claims description 4
235000019364 tetracycline Nutrition 0.000 claims description 4
150000003522 tetracyclines Chemical class 0.000 claims description 4
229930182555 Penicillin Natural products 0.000 claims description 3
150000002960 penicillins Chemical class 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
229940040944 tetracyclines Drugs 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 2
UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
229960001019 oxacillin Drugs 0.000 claims description 2
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 15
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 12
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 9
229940053050 neomycin sulfate Drugs 0.000 description 9
239000000843 powder Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 7
244000063299 Bacillus subtilis Species 0.000 description 6
235000014469 Bacillus subtilis Nutrition 0.000 description 6
241000222122 Candida albicans Species 0.000 description 6
239000002674 ointment Substances 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
241000191940 Staphylococcus Species 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
229940095731 candida albicans Drugs 0.000 description 5
239000000725 suspension Substances 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
244000005700 microbiome Species 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000654 additive Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
244000000010 microbial pathogen Species 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 description 2
IMLJLCJZQLGHJS-JEKSYDDFSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate Chemical compound O.O.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O IMLJLCJZQLGHJS-JEKSYDDFSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000004100 Oxytetracycline Substances 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
229960004348 candicidin Drugs 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
229940000425 combination drug Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
239000001095 magnesium carbonate Substances 0.000 description 2
229910000021 magnesium carbonate Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229960000625 oxytetracycline Drugs 0.000 description 2
235000019366 oxytetracycline Nutrition 0.000 description 2
244000052769 pathogen Species 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
239000006187 pill Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
RMVMLZHPWMTQGK-SOUFLCLCSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=CC=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O RMVMLZHPWMTQGK-SOUFLCLCSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
SVDOODSCHVSYEK-WOYDFFIASA-N (4s,5s,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)C3[C@H](O)C4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O SVDOODSCHVSYEK-WOYDFFIASA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000187708 Micromonospora Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000007765 cera alba Substances 0.000 description 1
CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012258 culturing Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
JCSGAUKCDAVARS-UHFFFAOYSA-N demethyltetracycline Natural products CN(C1C(=C(C(C2(C(=C3C(C4=C(C=CC=C4C(C3CC12)O)O)=O)O)O)=O)C(=O)N)O)C JCSGAUKCDAVARS-UHFFFAOYSA-N 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
238000010410 dusting Methods 0.000 description 1
FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
208000004396 mastitis Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
-1 oxytetracyclin dihydrate Chemical class 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002226 simultaneous effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940126572 wide-spectrum antibiotic Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL35341A 1969-09-30 1970-09-24 Antibiotic synergistic compositions containing primycin and another antibiotic and their preparation IL35341A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HUBU000503		1969-09-30

Publications (2)

Publication Number	Publication Date
IL35341A0 IL35341A0 (en)	1970-11-30
IL35341A true IL35341A (en)	1974-11-29

Family

ID=10993834

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL35341A IL35341A (en)	1969-09-30	1970-09-24	Antibiotic synergistic compositions containing primycin and another antibiotic and their preparation

Country Status (7)

Country	Link
US (1)	US3949077A (fr)
BE (1)	BE756856A (fr)
CA (1)	CA941299A (fr)
DE (1)	DE2047493A1 (fr)
FR (1)	FR2070099B1 (fr)
GB (1)	GB1330315A (fr)
IL (1)	IL35341A (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2737673A1 (de) *	1977-08-20	1979-02-22	Bayer Ag	Synergistische kombinationen von penicillinen
US4404189A (en) *	1981-01-21	1983-09-13	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.	Synergistic antimicrobial compositions
US4501732A (en) *	1981-01-21	1985-02-26	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.	Synergistic antimicrobial compositions
BE902010A (fr) *	1984-03-28	1985-09-25	Hajdusagi Agraripari Egyesules	Nouvelles combinaisons de medicaments ayant un effet synergique et procede pour les preparer.
HU196822B (en) *	1984-07-03	1989-01-30	Chinoin Gyogyszer Es Vegyeszet	Process for producing primicin salts
US5217707A (en) *	1988-06-16	1993-06-08	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.	Pharmaceutical composition and process for the preparation thereof
US20080138374A1 (en) *	2006-02-27	2008-06-12	Storey Daniel M	Molecular Plasma Deposition of Bioactive Small Molecules
HU230455B1 (hu)	2011-10-25	2016-07-28	Pannonpharma Gyógyszergyártó Zrt.	Primycin vagy primycin komponensek vagy ezek kombinációi mint speciális kórokozócsoportok által okozott fertőzések kezelésére vagy megelőzésére alkalmas gyógyszerhatóanyagok

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT268522B (de) *	1965-10-20	1969-02-10	Chinoin Gyogyszer Es Vegyeszet	Verfahren zur Herstellung von Primycin

0
- BE BE756856D patent/BE756856A/fr not_active IP Right Cessation
1970
- 1970-09-24 IL IL35341A patent/IL35341A/en unknown
- 1970-09-26 DE DE19702047493 patent/DE2047493A1/de active Pending
- 1970-09-29 GB GB4634670A patent/GB1330315A/en not_active Expired
- 1970-09-29 FR FR7035215A patent/FR2070099B1/fr not_active Expired
- 1970-09-30 US US05/076,985 patent/US3949077A/en not_active Expired - Lifetime
- 1970-09-30 CA CA094,444A patent/CA941299A/en not_active Expired

Also Published As

Publication number	Publication date
DE2047493A1 (de)	1971-04-22
FR2070099B1 (fr)	1974-08-23
BE756856A (fr)	1971-03-01
IL35341A0 (en)	1970-11-30
FR2070099A1 (fr)	1971-09-10
CA941299A (en)	1974-02-05
GB1330315A (en)	1973-09-19
US3949077A (en)	1976-04-06

Publication	Publication Date	Title
JPH0780774B2 (ja)	1995-08-30	薬剤組成物
RO115780B1 (ro)	2000-06-30	Combinatie sinergica
KR100738940B1 (ko)	2007-07-12	산화적-독성 물질, 특히 심장독성 물질에 대한 보호효과를가진 약물
US3949077A (en)	1976-04-06	Synergistic antibiotic compositions
CN1976723B (zh)	2010-12-29	制备治疗或预防感染性疾病的药物的用途
KR100420673B1 (ko)	2004-07-23	지연된구토반응을치료하기위한비강투여제
DE69125940T2 (de)	1997-12-18	Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
JP2650852B2 (ja)	1997-09-10	抗菌性配合製剤
EP2329819B1 (fr)	2019-05-01	Composition pharmaceutique destinée à être utilisée dans le traitement des infections sexuellement transmissibles
US3852453A (en)	1974-12-03	Method of enhancing vincamine compositions
JPH11508566A (ja)	1999-07-27	リファブチンを含む抗細菌相乗性組成物
KR20010022033A (ko)	2001-03-15	가축의 유선염 치료방법
US3156617A (en)	1964-11-10	Therapeutic compositions of kanamycin 2-(para-tertiary-amylphenoxy)-n-butyrate
JPH06505733A (ja)	1994-06-30	ミクロスポリディア症の治療におけるベンゾイミダゾール駆虫薬の使用
JPH01180825A (ja)	1989-07-18	感染症用剤
IT8247658A1 (it)	1983-07-27	Medicamenti a base di derivati condensati dell'imidazolo per il trattamento di disturbi urinari
US3328258A (en)	1967-06-27	Anti-microbial therapeutics consisting of nitrofurantoin, tetracycline, and d-glucosamine
Sharma et al.	2023	Cefuroxime Axetil: An oral prodrug of cefuroxime sodium
HU211305A9 (en)	1995-11-28	Novel method for treatment of parkinson's disease
KR100572090B1 (ko)	2006-04-17	상승작용이 있는 항균제 조성물, 그것을 함유하는 의약 및 소화기질환 치료제, 그들의 제조 방법, 및 그에 관련된 제제
GB2336999A (en)	1999-11-10	High-dosage triclosan compositions
WO1996008259A1 (fr)	1996-03-21	Composition antimicrobienne synergique
CA2113614A1 (fr)	1993-02-04	Methodes et compositions pour le traitement antimicrobien
Bergogne-Bérézin	1991	Pefloxacin
Cunha et al.	2002	Tetracycline pharmacodynamics